| Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial MT Seymour, LC Thompson, HS Wasan, G Middleton, AE Brewster, ... The Lancet 377 (9779), 1749-1759, 2011 | 484 | 2011 |
| Alpha‐6 integrin is necessary for the tumourigenicity of a stem cell‐like subpopulation within the MCF7 breast cancer cell line M Cariati, A Naderi, JP Brown, MJ Smalley, SE Pinder, C Caldas, ... International journal of cancer 122 (2), 298-304, 2008 | 307 | 2008 |
| A gene-expression signature to predict survival in breast cancer across independent data sets A Naderi, AE Teschendorff, NL Barbosa-Morais, SE Pinder, AR Green, ... Oncogene 26 (10), 1507-1516, 2007 | 304 | 2007 |
| A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer A Naderi, L Hughes-Davies Neoplasia 10 (6), 542-548, 2008 | 202 | 2008 |
| A 1 Mb minimal amplicon at 8p11–12 in breast cancer identifies new candidate oncogenes MJ Garcia, J Pole, SF Chin, A Teschendorff, A Naderi, H Ozdag, M Vias, ... Oncogene 24 (33), 5235-5245, 2005 | 178 | 2005 |
| The 17q23 amplicon and breast cancer CS Sinclair, M Rowley, A Naderi, FJ Couch Breast cancer research and treatment 78, 313-322, 2003 | 177 | 2003 |
| Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers SF Chin, Y Wang, NP Thorne, AE Teschendorff, SE Pinder, M Vias, ... Oncogene 26 (13), 1959-1970, 2007 | 131 | 2007 |
| A consensus prognostic gene expression classifier for ER positive breast cancer AE Teschendorff, A Naderi, NL Barbosa-Morais, SE Pinder, IO Ellis, ... Genome biology 7, 1-13, 2006 | 115 | 2006 |
| TBX2 is preferentially amplified in BRCA1-and BRCA2-related breast tumors CS Sinclair, C Adem, A Naderi, CL Soderberg, M Johnson, L Wadum, ... Cancer research 62 (13), 3587-3591, 2002 | 114 | 2002 |
| BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-κB inhibition of apoptosis in breast cancer cell lines A Naderi, AE Teschendorff, J Beigel, M Cariati, IO Ellis, JD Brenton, ... Cancer research 67 (14), 6725-6736, 2007 | 105 | 2007 |
| A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer KM Chia, J Liu, GD Francis, A Naderi Neoplasia 13 (2), 154-166, 2011 | 102 | 2011 |
| PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer AE Teschendorff, A Naderi, NL Barbosa-Morais, C Caldas Bioinformatics 22 (18), 2269-2275, 2006 | 79 | 2006 |
| Expression microarray reproducibility is improved by optimising purification steps in RNA amplification and labelling A Naderi, AA Ahmed, NL Barbosa-Morais, S Aparicio, JD Brenton, ... BMC genomics 5, 1-14, 2004 | 70 | 2004 |
| Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer A Naderi, KM Chia, J Liu Breast Cancer Research 13, 1-16, 2011 | 68 | 2011 |
| Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer A Naderi, M Meyer, DH Dowhan Neoplasia 14 (4), 283-IN3, 2012 | 66 | 2012 |
| BEX2 regulates mitochondrial apoptosis and G1 cell cycle in breast cancer A Naderi, J Liu, IC Bennett International journal of cancer 126 (7), 1596-1610, 2010 | 63 | 2010 |
| BRCA2 and pancreatic cancer A Naderi, FJ Couch International journal of gastrointestinal cancer 31, 99-106, 2002 | 59 | 2002 |
| Coagulation factor VII is regulated by androgen receptor in breast cancer A Naderi Experimental cell research 331 (1), 239-250, 2015 | 56 | 2015 |
| Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer A Naderi, M Meyer Breast Cancer Research 14, 1-16, 2012 | 48 | 2012 |
| Prolactin-induced protein in breast cancer A Naderi Recent Advances in Prolactin Research, 189-200, 2015 | 47 | 2015 |
